Cargando…

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials

Objective: This network meta-analysis will provide a complete toxicity profile, toxicity profile, and safety ranking of immune checkpoint inhibitors (ICIs) for treatment of advanced non-small cell lung cancer (NSCLC). Methods: We found 12 phase II or III randomized clinical trials (RCTs) including 8...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Weidong, Gu, Jingjing, Bian, Chunming, Huang, Guanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574003/ https://www.ncbi.nlm.nih.gov/pubmed/34759817 http://dx.doi.org/10.3389/fphar.2021.686876

Ejemplares similares

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
por: Gao, Ling, et al.
Publicado: (2019)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
por: Liu, Hao, et al.
Publicado: (2023)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Da, Lijun, et al.
Publicado: (2020)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis
por: Xiao, Qionghua, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study
por: Les, Iñigo, et al.
Publicado: (2022)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
por: Sung, Mike, et al.
Publicado: (2020)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
por: Lin, Li, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Immune-related adverse events with immune checkpoint inhibitors: Special reference to the effects on the lungs
por: Hirata, Aya, et al.
Publicado: (2021)

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
por: Zhou, Lin, et al.
Publicado: (2021)

Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
por: Kato, Koki, et al.
Publicado: (2022)

The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non–Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
por: Chai, Qing-Qing, et al.
Publicado: (2019)

Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis
por: Liu, Zijing, et al.
Publicado: (2023)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
por: Ma, Ke, et al.
Publicado: (2018)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
por: Song, Peng, et al.
Publicado: (2020)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
por: Chitturi, Kalyan R., et al.
Publicado: (2019)

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis
por: Zhang, Yue, et al.
Publicado: (2023)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
por: Lee, Jii Bum, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ekqo7vfeqc7f8jr67vhiitheol